Aterosclerose: Acesso Aberto

Abstrato

Short Review: Lipid-Lowering Therapies, Where are we Heading?

Willemien van Zwol, Peter J Lansberg and Jan Albert Kuivenhoven*

With the presently available drugs, low-density lipoprotein cholesterol (LDL-c) can be reduced to current guideline recommendations. Despite very low LDL-c, patients continue to experience atherosclerotic cardiovascular disease (ASCVD) complications. To address this “residual” risk, new potentially manageable lipoproteins have become the next therapeutic targets, i.e. Lp(a) and triglyceride rich lipoproteins (TRL).